Cytodyn Inc (CYDY)

[Saltz]

I can't help but get a little excited as I look at the upside. If the data is strong from both Adjunct PE and interim data on first 100 patients, BTD would be granted shortly thereafter-probably a few months as the FDA would take the 60 days again-hence moving BTD to 2H 2017. Those events in addition to a large percentage of patients on the extension arm from Adjunct could likely trigger a buyout. Think about it, if the data is strong this could likely be the end of the road.

IMO Tony C was not brought in to replace Nader. He may be assisting and guiding with regards to FDA, however his major emphasis is on packaging a deal based on the events above having positive outcomes. We will find out on the next conference call. I for one will ask, if it is not addressed, how do Nader's and Tony's job descriptions and responsibilities differ? Are they in equal positions of authority? What has changed in Nader's responsibilities since Tony was brought on in his new role as Executive Chairman?

A tweet for a .60 to $6 move is a distinct possibility in the not so distant future.